What Researchers Did
Researchers conducted a literature review, informed by two case experiences, to propose medical management options for refractory haematuria in palliative patients.
What They Found
The review highlighted a limited evidence base for managing refractory haematuria in palliative patients. The authors reported successful use of a nonconjugated oestrogen, which carries a lower venous thromboembolism risk compared to conjugated oestrogens, in their two cases.
What This Means for Canadian Patients
Canadian palliative patients experiencing refractory haematuria may benefit from the proposed medical management strategies, including the consideration of nonconjugated oestrogen. This approach could offer alternative options for symptom control, potentially improving quality of life when standard measures are ineffective.
Canadian Relevance
This study has no direct Canadian connection.
Study Limitations
A key limitation is the limited evidence base identified in the literature review, which was informed by only two case experiences.